(Q51489539)

5 April 2018

title

Characterization of insulin secretion in Valproate-treated patients with epilepsy. (English)

1 reference

5 April 2018

1 reference

Mikael Knip

3

0 references

author name string

Virpi Pylvänen

series ordinal

1

1 reference

5 April 2018

Arto Pakarinen

series ordinal

2

1 reference

5 April 2018

Jouko Isojärvi

series ordinal

4

1 reference

5 April 2018

publication date

1 September 2006

1 reference

5 April 2018

published in

Epilepsia

1 reference

5 April 2018

volume

47

1 reference

5 April 2018

issue

9

1 reference

5 April 2018

page(s)

1460-1464

1 reference

5 April 2018

Divalproex sodium in migraine prophylaxis: a dose-controlled study

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Obesity and endocrine disorders in women taking valproate for epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Valproate therapy and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Valproate and mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Fasting serum insulin and lipid levels in men with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Clustering of cardiovascular risk factors in confirmed prehypertensive individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Altered ovarian function and cardiovascular risk factors in valproate-treated women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Anticardiolipin and antinuclear antibodies in epilepsy--a population-based cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Metabolic changes during treatment with valproate in humans: implication for untoward weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Hyperinsulinism of hepatic cirrhosis: Diminished degradation or hypersecretion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Decreased hepatic insulin extraction in subjects with mild glucose intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Serum insulin and leptin levels in valproate-associated obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2006.00546.X

10.1111/J.1528-1167.2006.00546.X

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018